These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 23225450)

  • 1. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
    Gigante M; Li G; Ferlay C; Perol D; Blanc E; Paul S; Zhao A; Tostain J; Escudier B; Negrier S; Genin C
    Anticancer Res; 2012 Dec; 32(12):5447-51. PubMed ID: 23225450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
    Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
    Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
    Li G; Feng G; Gentil-Perret A; Genin C; Tostain J
    J Urol; 2008 Aug; 180(2):510-3; discussion 513-4. PubMed ID: 18550116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
    Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B
    Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA9 as a molecular marker for differential diagnosis of cystic renal tumors.
    Li G; Bilal I; Gentil-Perret A; Feng G; Zhao A; Peoc'h M; Genin C; Tostain J; Gigante M
    Urol Oncol; 2012; 30(4):463-8. PubMed ID: 20822935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma.
    Papworth K; Sandlund J; Grankvist K; Ljungberg B; Rasmuson T
    Anticancer Res; 2010 Jul; 30(7):2953-7. PubMed ID: 20683038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
    BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
    Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
    Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
    Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.
    Jobard E; Blanc E; Négrier S; Escudier B; Gravis G; Chevreau C; Elena-Herrmann B; Trédan O
    Br J Cancer; 2015 Oct; 113(8):1148-57. PubMed ID: 26372698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
    Schmidinger M; Zielinski CC
    Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy.
    Li G; Feng G; Gentil-Perret A; Genin C; Tostain J
    Clin Exp Metastasis; 2007; 24(3):149-55. PubMed ID: 17390110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C; Szczylik C
    Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
    de Martino M; Klatte T; Seligson DB; LaRochelle J; Shuch B; Caliliw R; Li Z; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    J Urol; 2009 Aug; 182(2):728-34. PubMed ID: 19539328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
    Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
    Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
    Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
    Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.